cp-96345

CP-96345 is a potent and selective non-peptide antagonist of the neurokinin 1 (NK1) receptor, which is the primary receptor for substance P. It inhibits substance P-induced responses such as salivary secretion and neurogenic inflammation in vivo. CP-96345 has been shown to block tachykinin-mediated vasodilation and plasma protein extravasation associated with neurogenic inflammation, demonstrating oral activity and high specificity for NK1 receptors[1][4][5]. The drug was developed by Pfizer primarily as a research tool to study the role of substance P in pain transmission, inflammation, asthma-related inflammatory processes, and HIV infection mechanisms[3][7][8]. In preclinical studies, CP-96345 also inhibited HIV replication in monocyte-derived macrophages by antagonizing NK1 receptors and downregulating CCR5 expression[7][8].

Other names

(2S,3S)-N-(2-Methoxyphenyl)methyl-2-diphenylmethyl-1-azabicyclo[2.2.2]octan-3-amine